Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
Saskia J RaeuberMelanie KorsenNiklas HuntemannLeoni RolfesThomas MünteferingVera DobelmannAlexander M HermannTristan KölscheKarin von Wnuck LipinskiChristina B SchroeterChristopher NelkeLiesa Regner-NelkeJens IngwersenMarc PawlitzkiBianca TeegenMichael Harry BarnettHans-Peter HartungOrhan AktasPhilipp AlbrechtBodo LevkauNico MelzerTobias RuckSven G MeuthDavid KremerPublished in: Journal of neurology, neurosurgery, and psychiatry (2022)
In OCR-treated patients with MS, the humoral immune response to SARS-CoV-2 vaccination is attenuated while the T cell response is preserved. However, it is still unclear whether T or B cell-mediated immunity is required for effective clinical protection. Nonetheless, given the long-lasting clinical effects of OCR, monitoring of peripheral B cell counts could facilitate individualised treatment regimens and might be used to identify the optimal time to vaccinate.